Protac degrader

Show results for

Unknown (217)
Proteomics (131)
Genomics (97)
Transcriptomics (42)
Other (2)

Organisms

Aerococcus urinae NBRC 15544 = CCUG 36881 (115)
Allexis (115)
Canis lupus familiaris (115)
Carya cathayensis (115)
Clostridioides difficile 630 (115)
Cyanophora paradoxa (115)
Ensifer adhaerens (115)
Enterococcus faecalis (115)
Globicatella sanguinis (115)
Histomonas meleagridis (115)
Human immunodeficiency virus 1 (115)
Listeria monocytogenes (115)
Marchantia polymorpha (115)
Methylohalobius crimeensis 10Ki (115)
Mus musculus (115)
Mycobacterium tuberculosis (115)
Ophrys garganica (115)
Ophrys sphegodes (115)
Physcomitrium patens (115)
Pseudomonas aeruginosa SJTD-1 (115)
Pseudomonas putida KT2440 (115)
Rattus norvegicus (115)
Rhizobium sp. Leaf68 (115)
Schizosaccharomyces pombe 927 (115)
Schizosaccharomyces pombe 972h- (115)
Shigella (115)
Sphingomonas sp. Leaf257 (115)
Homo sapiens (67)
Mus musculus (7)
Drosophila melanogaster (1)

Organisms

Homo sapiens (65)
Mus musculus (6)
unidentified (1)

Repository

pride (115)
ENA (77)
geo (64)
iProX (8)
MassIVE (7)
biostudies-arrayexpress (1)

Tissue

Cell culture (74)
Epithelial cell (7)
Blood cell (4)
Blood (3)
Cell suspension culture (3)
Colon epithelial cell (3)
B cell (2)
Fibroblast (2)
Macrophage (2)
Permanent cell line cell (2)
Blood platelet (1)
Cervix epithelium (1)
Early embryonic cell (1)
Epithelial cell of pancreas (1)
HL-60 cell (1)
HeLa cell (1)
Head and neck squamous cell carcinoma cell (1)
Head and neck squamous cell carcinoma cell line (1)
Hepatocyte (1)
Kidney (1)
Liver (1)
Lung epithelial cell differentiation (1)
Lymph node (1)
Myeloid cell (1)
Neuron (1)
Pancreas (1)
Platelet (1)
Thyroid gland (1)

Disease

Acute leukemia (5)
Disease free (5)
Colon cancer (4)
Prostate adenocarcinoma (3)
Breast cancer (2)
Adult hepatocellular carcinoma (1)
COVID-19 (1)
Cervical adenocarcinoma (1)
Endocervical adenocarcinoma (1)
Frontotemporal dementia (1)
Influenza (1)
Lung adenocarcinoma (1)
Lymphoma (1)
Malignant neoplasm of ovary (1)
Neuroblastoma (1)
Pancreatic cancer (1)
Pancreatic ductal adenocarcinoma (1)
Parkinson's disease (1)

Technology Type

Mass Spectrometry (115)
Shotgun proteomics (70)
Bottom-up proteomics (22)
Data-dependent acquisition (19)
Data-independent acquisition (11)
Gel-based experiment (3)
Affinity purification coupled with mass spectrometry proteomics (2)
All-ion fragmentation (2)
Affinity proteomics (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)
PAcIFIC (1)
Top-down proteomics (1)

Instrument Platform

Orbitrap Fusion Lumos (3)
Orbitrap Exploris 480 (2)
Agilent TapeStation (1)
Element AVITI (1)
None (1)
Orbitrap Eclipse (1)
TimsTOF HT (1)
TimsTOF Pro 2 (1)
TimsTOF SCP (1)

Publication Date

2025 (42)
2021 (35)
2024 (31)
2026 (26)
2023 (25)
2022 (18)
2019 (8)
2020 (6)
2018 (3)
2017 (1)

First Public Date

2024 (20)
2026 (16)
2025 (15)
2022 (11)
2021 (7)
2023 (6)
2019 (1)
2018 (1)

Study type

RNA-seq of coding RNA (1)

Release Date

2025 (53)
2024 (48)
2023 (33)
2022 (27)
2021 (19)
2020 (12)
2026 (10)
2019 (9)
2018 (4)
2017 (2)
2016 (1)

Lab affiliation

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (48)
Analytics Core Facility Essen (ACE), Chemische Biologie, Universität Duisburg-Essen, ZMB, Germany (4)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA (3)
Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany German Cancer Consortium (DKTK) Mainz/Frankfurt, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany (3)
Cancer Research UK Scotland Institute (Formerly the Cancer Research UK Beatson Institute) Garscube Estate Switchback Road Bearsden Glasgow, G61 1BD (2)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (2)
Senior Director, Dynamic Omics, CGR, One Medimmune Way Gaithersburg, MD 20878 (2)
Technical University of Munich, Chair of Proteomics and Bioanalytics, Emil-Erlenmeyer-Forum 5, 85354 Freising, Germany (2)
University of Dundee, Scool of Life Sciences, Department of Molecular, Cellular andDevelopmental biology (2)
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA 2Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA (1)
2Departments of Internal Medicine, University of Michigan, Ann Arbor MI 48109, USA. (1)
Arvinas Operations, Inc., 5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511 United States (1)
BCMP, Harvard Medical School, Boston, USA Cancer Biology, Dana-Farber Cancer Institute, Boston, USA (1)
Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (1)
Biomedical Research Novartis Pharma AG (1)
Cancer Biology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States (1)
CeMM Principal Investigator (1)
Centre For Targeted Protein Degradation, Unniversity of Dundee, UK (1)
Centre for Targeted Protein Degradation (CeTPD) University of Dundee (1)
Centre for Targeted Protein Degradation, Dundee, UK (1)
Centre for targeted protein degradation, University of Dundee (1)
Charité – Universitätsmedizin Berlin (1)
Department of Biomolecular Medicine, Faculty of Medicine & Health Sciences, Ghent University, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium (1)
Department of Biomolecular Medicine, Faculty of Medicine & Health Sciences, Ghent University, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. (1)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, (1)
Department of Chemistry Northwestern University (1)
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (1)
Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA (1)
Department of Pharmacodynamics, University of Florida (1)
Department of Urology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China. Frontier Science Center for Immunology and Metabolism,Medical Research Institute,Wuhan University,Wuhan 430071,China. (1)

Previous page
1 / 49
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 49
Next page

Sort by:

Relevance

Page size

MAGL Targeted PROTAC Degrader Simultaneously Enhances P53 for Synergistic Treatment of Glioblastoma Stem Cell

This study focuses on the protein degradation effects of the MAGL inhibitor JZL184 and the newly synthesized MAGL-PROTAC on MAGL.

ORGANISM(S): Homo Sapiens

2024-12-02 | PXD058506 |

Discovery of an LSD1 PROTAC degrader.

Not available

S-EPMC12107161 | biostudies-literature

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader.

Not available

S-EPMC11069391 | biostudies-literature

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Not available

S-EPMC7354697 | biostudies-literature

BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis.

Not available

S-EPMC12828559 | biostudies-literature

Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer.

Not available

S-EPMC12557393 | biostudies-literature

Characterization of SGK3-PROTAC1, a highly specific SGK3 kinase PROTAC degrader

SGK3 is a PX domain containing protein kinase activated at endosomes downstream of Class 1 and 3 PI3K family members by growth factors and oncogenic mutations. SGK3 plays a key role in mediating resistance of breast cancer to Class 1 PI3K or Akt inhibitors, by substituting for loss of Akt and restor...

ORGANISM(S): Homo sapiens (Human)

2019-11-12 | PXD013779 | Pride

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.

Not available

S-EPMC7606109 | biostudies-literature

Discovery of the First-in-class G9a/GLP PROTAC Degrader.

Not available

S-EPMC10925177 | biostudies-literature

Discovery of the First-in-Class G9a/GLP PROTAC Degrader.

Not available

S-EPMC11069390 | biostudies-literature

Previous page
1 / 49
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 49
Next page

Sort by:

Relevance

Page size

489 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

First Public Date

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets